Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02494141 · ClinicalTrials.gov registry record · Phase 4

Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD

A Phase 4 study, sponsored by University of Colorado, Denver.

Completed
Registry status
Phase 4
Development phase
68
Enrollment target

NCT02494141: Completed Phase 4 study, sponsored by University of Colorado, Denver.

NCT02494141 is a Phase 4 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 68 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02494141, a Phase 4 study, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
Phase 4
Development phase
68 participants
Enrollment target

Study Summary

The proposed research will determine the effectiveness of curcumin for improving the health and function of arteries in children and young adults with autosomal dominant polycystic kidney disease (ADPKD). The study also will provide insight into how curcumin improves artery health by determining the physiological mechanisms (biological reasons) involved and offer exploratory evidence if curcumin can slow kidney growth. This will be done by comparing these measurements in children and young adults who are randomized to receive either curcumin or placebo for 1 year.

Primary Outcome

co-primary endpoint

Interventions

  • OTHER Placebo
  • DRUG Curcumin

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2015-11-12
Est. Completion 2021-02-01
Phase Phase 4
University of Colorado, Denver

1,283 total trials

What the finished NCT02494141 record still lists

NCT02494141 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02494141 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02494141 about?

NCT02494141 is a clinical study titled "Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD". The proposed research will determine the effectiveness of curcumin for improving the health and function of arteries in children and young adults with autosomal dominant polycystic kidney disease (ADPKD). The study also will provide insight into how curcumin improves artery health by determining the...

What is the current status of trial NCT02494141?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 68 participants. The study started on 2015-11-12. Estimated completion is 2021-02-01.

What interventions are being tested in trial NCT02494141?

The interventions under investigation include: Placebo (OTHER), Curcumin (DRUG).

Who is sponsoring clinical trial NCT02494141?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02494141's enrollment target sits among peer trials

68 1076th of 2000 higher than 918 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02044497 · 68 participants · Phase 4

    Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients

  • NCT03779854 · 68 participants · Phase 2

    Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

  • NCT03821246 · 68 participants · Phase 2

    Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

  • NCT04115514 · 68 participants · Phase 2

    Treatment of ARDS With Instilled T3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02494141, the US trial registry maintained by the National Library of Medicine. NCT02494141 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.